1. World Health Organization. Global tuberculosis report 2016. [Accessed November 2016]. Available in URL: http://reliefweb.int/sites/reliefweb.int/files/resources/gtbr2016_main_text.pdf.
2. Wright A, Zignol M. WHO/IUATLD. Anti-tuberculosis Drug Resistance in the world: fourth global report.2002-2007. Geneva, Switzerland: World Health Organization; 2008. [Accessed November 2016]. Available URL: http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf.
3. Drug resistance in Mexico: results from the National Survey on Drug-Resistant Tuberculosis;I Bojorquez-Chapela;The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease,2013
4. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council;Am Rev Respir Dis,1991
5. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries;MA Espinal;Jama,2000